Are you Dr. Steed?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5200 Centre Ave
Suite 307
Pittsburgh, PA 15232Phone+1 412-623-3333
Summary
- Dr. David Steed, MD is a vascular surgeon in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
UPMC Medical Education (Pittsburgh)Residency, Surgery, 1977 - 1980- UPMC Medical Education (Pittsburgh)Residency, Surgery, 1973 - 1976
University of Pittsburgh School of MedicineClass of 1973
Certifications & Licensure
PA State Medical License 1974 - 2024
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- ST266 Versus Standard Care In Treating Partial Thickness Burns Start of enrollment: 2009 Jun 01
- Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS) Start of enrollment: 2014 Mar 01
- ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects Start of enrollment: 2019 Jun 10
- Join now to see all
Publications & Presentations
PubMed
- 73 citationsProgression of asymptomatic carotid stenosis: a natural history study in 1004 patients.Satish C. Muluk, Visala S. Muluk, Hiroatsu Sugimoto, Robert Y. Rhee, Jeffrey D Trachtenberg
Journal of Vascular Surgery. 1999-02-01 - 77 citationsCauses of stroke in carotid endarterectomy.David L. Steed, Andrew B. Peitzman, Grundy Bl, Marshall W. Webster
Surgery. 1982-10-01 - 148 citationsClinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.David L. Steed
Plastic and Reconstructive Surgery. 2006-06-01
Press Mentions
Noveome Biotherapeutics, Inc. : To Present at 10th Annual Glaucoma 360 Virtual MeetingJanuary 27th, 2021
Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and BrainSeptember 26th, 2019
